Vitamin D deficiency increases vulnerability to canagliflozin-induced adverse effects on 1,25-dihydroxyvitamin D and PTH.

Zhinous Shahidzadeh YazdiElizabeth A StreetenHilary B WhitlatchMay E MontasserAmber L BeitelsheesSimeon I Taylor

Published in: The Journal of clinical endocrinology and metabolism (2023)

VitD deficiency rendered individuals more vulnerable to adverse effects of canagliflozin on biomarkers associated with bone health. VitD3 supplementation was protective against canagliflozin's short-term adverse effects on 1,25(OH)2D and PTH.

Keyphrases

healthcare
public health
climate change
mental health
adverse drug
high glucose
emergency department
human health
bone loss